<p>與日內交易相比，長期持有公司的股票有顯著的優勢。買入並持有的方法更簡單，不會讓投資者受到短期且常常不理性的市場情緒的影響，限制了費用和税收，並且（尤其是在再投資股息的情況下）充分利用了複利的魔力。</p>
<p>儘管如此，即使在股息股票中，許多股票也不值得長期持有。讓我們考慮一個值得長期持有的股息支付者：<strong>雅培</strong>（Abbott Laboratories）（ABT -2.47%）。這家醫療保健領導者具備成為永恆股票的特質。讓我來解釋一下。</p>
<h2>雅培的業務可能會彎曲，但不會崩潰</h2>
<p>大多數公司不會經營幾十年。有時，甚至整個行業由於技術進步而變得過時。然而，在醫療保健行業，這種情況不太可能發生，雅培在該領域是領先者。由於多種原因，尤其是人口老齡化，醫療服務的需求預計將持續上升。醫學在幫助我們活得更長、更健康方面的進步導致了對進一步發展的需求不斷增長。</p>
<p>這對該行業來説是個好消息，但並不保證雅培的成功。為什麼這家公司值得永遠持有？以下是三個理由。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzczMzgvc3VyZ2VvbnMtaW4tYW4tb3BlcmF0aW5nLXJvb20uanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzczMzgvc3VyZ2VvbnMtaW4tYW4tb3BlcmF0aW5nLXJvb20uanBnJnc9NzAw"/></p>
<p>圖片來源：Getty Images。</p>
<p>首先，雅培實驗室是其醫療設備專業領域中最成熟的公司之一，開發了數十種醫生常用的產品。它與醫生建立了良好的聲譽和關係，這為其提供了顯著的優勢。</p>
<p>其次，雅培具有出色的創新能力——這是跟上行業需求變化的關鍵。該公司的某些產品在其細分市場中處於行業領先地位。其 MitraClip 是修復二尖瓣反流的頂級產品之一，開創了在該領域使用微創方法的先河。Amplatzer Occluder 設備系列幫助提高了心臟異常開口微創治療的標準。</p>
<p>雅培的 FreeStyle Libre 系列，作為一系列連續血糖監測（CGM）系統，也在其領域中處於領先地位；它幫助開創了創新的 CGM 方法，相較於傳統血糖儀顯示出臨牀優勢。FreeStyle Libre 已成為歷史上銷售額最高的醫療設備，突顯了雅培的突破如何支持其產生強勁財務業績的能力。</p>
<p>更重要的是，FreeStyle Libre 系列仍然擁有巨大的增長空間。正如雅培所指出的，CGM 市場的滲透率極低，全球只有約 1% 的糖尿病患者能夠使用 CGM 技術。這就是為什麼該公司的糖尿病護理部門近年來成為其主要增長動力之一，並且這一趨勢預計將持續一段時間。</p>
<p>第三，雅培的整體業務是多元化的。雖然它以醫療設備的工作而聞名，但公司在品牌仿製藥、診斷和營養等領域也有業務。這種多樣性使其能夠應對任何特定業務單元的挑戰。值得指出的是，雅培的營養品牌包括著名的 Ensure 和 Similac。</p>
<p>因此，雅培銷售的產品在經濟條件下仍然保持高需求。它不斷創新，在行業中擁有深厚的根基，並且有多個增長途徑。股票可能會經歷下跌，但即使在最糟糕的情況下也應該能夠生存，並在之後繼續表現良好。</p>
<h2>雅培擁有令人印象深刻的股息記錄</h2>
<p>鑑於雅培業務的強勁，雅培擁有如此優秀的股息計劃並不令人驚訝。幾年前，它加入了股息之王的精英羣體，這些公司已經連續提高股息至少 50 年；這家醫療設備巨頭現在已經連續 53 年提高股息，並且沒有結束的跡象。其現金支付比率約為 60.4%，這仍然是合理的，併為進一步增長股息提供了更多空間。</p>
<p>雅培實驗室應該能夠為長期投資者提供優異的回報，尤其是對於那些再投資股息的股東。</p>

雅培

<p>雅培（Abbott Laboratories，股票代碼：ABT）被認為是長期投資的頂級分紅股票，原因在於其在醫療保健領域的強大市場地位、創新產品和多元化的業務板塊。該公司在醫療專業人士中享有良好的聲譽和關係，這增強了其競爭優勢。雅培的 FreeStyle Libre 是一款領先的連續血糖監測系統，體現了其創新和增長潛力。雅培連續 53 年提高分紅，且合理的派息比率為 60.4%，因此在長期回報方面表現出色，尤其適合那些選擇再投資分紅的投資者</p>

<p>There are significant advantages to holding shares of companies for a long time as opposed to, say, day trading. The buy-and-hold approach is simpler, doesn't leave investors at the mercy of short-term and often irrational market sentiment, limits fees and taxes, and (especially when dividends are reinvested) puts the magic of compounding to work.</p>
<div class="lb-trans"><p>與日內交易相比，長期持有公司的股票有顯著的優勢。買入並持有的方法更簡單，不會讓投資者受到短期且常常不理性的市場情緒的影響，限制了費用和税收，並且（尤其是在再投資股息的情況下）充分利用了複利的魔力。</p>
</div><p>That being said, even among dividend stocks, many aren't worth sticking with for the long term. Let's consider one dividend payer that is: <strong>Abbott Laboratories</strong>(ABT -2.47%). This healthcare leader has the qualities of a forever stock. Let me explain.</p>
<div class="lb-trans"><p>儘管如此，即使在股息股票中，許多股票也不值得長期持有。讓我們考慮一個值得長期持有的股息支付者：<strong>雅培</strong>（Abbott Laboratories）（ABT -2.47%）。這家醫療保健領導者具備成為永恆股票的特質。讓我來解釋一下。</p>
</div><h2>Abbott's business might bend, but it won't break</h2>
<div class="lb-trans"><h2>雅培的業務可能會彎曲，但不會崩潰</h2>
</div><p>Most companies don't stay in business for decades. Sometimes, even entire industries become obsolete due to technological advances. The latter is unlikely to happen in the healthcare sector, where Abbott Laboratories is a leading player. The demand for medical services should remain on the rise for a slew of reasons, particularly an aging population. Medicine's progress in helping us live longer and healthier lives has led to a growing need for further advancements.</p>
<div class="lb-trans"><p>大多數公司不會經營幾十年。有時，甚至整個行業由於技術進步而變得過時。然而，在醫療保健行業，這種情況不太可能發生，雅培在該領域是領先者。由於多種原因，尤其是人口老齡化，醫療服務的需求預計將持續上升。醫學在幫助我們活得更長、更健康方面的進步導致了對進一步發展的需求不斷增長。</p>
</div><p>That's excellent news for the sector, but it doesn't guarantee Abbott Laboratories' success. Why is the company worth sticking with forever? Here are three reasons.</p>
<div class="lb-trans"><p>這對該行業來説是個好消息，但並不保證雅培的成功。為什麼這家公司值得永遠持有？以下是三個理由。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzczMzgvc3VyZ2VvbnMtaW4tYW4tb3BlcmF0aW5nLXJvb20uanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F837338%2Fsurgeons-in-an-operating-room.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><p>First, Abbott Labs is one of the most well-established companies in its medical device specialty, and has developed dozens of products that physicians routinely use. It has built a strong reputation and relationships with doctors, which grant it a significant advantage.</p>
<div class="lb-trans"><p>首先，雅培實驗室是其醫療設備專業領域中最成熟的公司之一，開發了數十種醫生常用的產品。它與醫生建立了良好的聲譽和關係，這為其提供了顯著的優勢。</p>
</div><p>Second, Abbott has an excellent innovative streak -- that's the key to keeping pace with the changing demands of the sector. Some of the company's products are among the industry leaders in their niches. Its MitraClip is one of the top products used to fix mitral valve regurgitation, having pioneered the use of minimally invasive approaches in this area. The family of Amplatzer Occluder devices helped raise the standard for the minimally invasive treatment of abnormal openings in the heart.</p>
<div class="lb-trans"><p>其次，雅培具有出色的創新能力——這是跟上行業需求變化的關鍵。該公司的某些產品在其細分市場中處於行業領先地位。其 MitraClip 是修復二尖瓣反流的頂級產品之一，開創了在該領域使用微創方法的先河。Amplatzer Occluder 設備系列幫助提高了心臟異常開口微創治療的標準。</p>
</div><p>Abbott's FreeStyle Libre franchise, a family of continuous glucose monitoring (CGM) systems, is also among the leaders in its area; it helped pioneer the innovative CGM approach, which shows clinical benefits over traditional blood glucose meters. The FreeStyle Libre has become the most successful medical device in history in terms of dollar sales, highlighting how Abbott's breakthroughs support its ability to generate strong financial results.</p>
<div class="lb-trans"><p>雅培的 FreeStyle Libre 系列，作為一系列連續血糖監測（CGM）系統，也在其領域中處於領先地位；它幫助開創了創新的 CGM 方法，相較於傳統血糖儀顯示出臨牀優勢。FreeStyle Libre 已成為歷史上銷售額最高的醫療設備，突顯了雅培的突破如何支持其產生強勁財務業績的能力。</p>
</div><p>What's more, the FreeStyle Libre franchise still has a massive growth runway ahead. As Abbott has pointed out, the CGM market is severely underpenetrated, as only about 1% of diabetes patients worldwide have access to CGM technology. That's why the company's diabetes care segment has been one of its major growth drivers in recent years, and this trend should continue for a while.</p>
<div class="lb-trans"><p>更重要的是，FreeStyle Libre 系列仍然擁有巨大的增長空間。正如雅培所指出的，CGM 市場的滲透率極低，全球只有約 1% 的糖尿病患者能夠使用 CGM 技術。這就是為什麼該公司的糖尿病護理部門近年來成為其主要增長動力之一，並且這一趨勢預計將持續一段時間。</p>
</div><p>Third, Abbott's overall business is diversified. While it's best known for its work in medical devices, the company also has segments in branded generic pharmaceuticals, diagnostics, and nutrition. This diversity can allow it to navigate challenges in any particular business unit. It's also worth pointing out that Abbott's nutrition brands include famous ones like Ensure and Similac.</p>
<div class="lb-trans"><p>第三，雅培的整體業務是多元化的。雖然它以醫療設備的工作而聞名，但公司在品牌仿製藥、診斷和營養等領域也有業務。這種多樣性使其能夠應對任何特定業務單元的挑戰。值得指出的是，雅培的營養品牌包括著名的 Ensure 和 Similac。</p>
</div><p>So, Abbott markets products that remain in high demand regardless of economic conditions. It constantly innovates, has deep footprints in the industry, and has several growth avenues. The stock might experience a downturn, but should survive even the worst and continue performing well long afterward.</p>
<div class="lb-trans"><p>因此，雅培銷售的產品在經濟條件下仍然保持高需求。它不斷創新，在行業中擁有深厚的根基，並且有多個增長途徑。股票可能會經歷下跌，但即使在最糟糕的情況下也應該能夠生存，並在之後繼續表現良好。</p>
</div><h2>Abbott boasts an impressive dividend track record</h2>
<div class="lb-trans"><h2>雅培擁有令人印象深刻的股息記錄</h2>
</div><p>Given the strength of Abbott's business, it's not surprising that it has such an excellent dividend program. It joined the elite group of Dividend Kings, companies that have raised their payouts for at least 50 consecutive years, just a few years ago; the medical device giant has now had 53 straight years of dividend hikes, and there's no end in sight. Its cash payout ratio is about 60.4%, which is still reasonable and grants plenty more room to grow the dividend further.</p>
<div class="lb-trans"><p>鑑於雅培業務的強勁，雅培擁有如此優秀的股息計劃並不令人驚訝。幾年前，它加入了股息之王的精英羣體，這些公司已經連續提高股息至少 50 年；這家醫療設備巨頭現在已經連續 53 年提高股息，並且沒有結束的跡象。其現金支付比率約為 60.4%，這仍然是合理的，併為進一步增長股息提供了更多空間。</p>
</div><p>Abbott Laboratories should provide excellent long-term returns, especially for shareholders who reinvest the dividend.</p>
<div class="lb-trans"><p>雅培實驗室應該能夠為長期投資者提供優異的回報，尤其是對於那些再投資股息的股東。</p>
</div>

一隻值得長期買入並持有的無腦股息股票